CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.26 USD | -10.64% |
|
-8.03% | -57.00% |
Financials (USD)
| Sales 2024 * | 15.52M | Sales 2025 * | 7.2M | Capitalization | 52.34M |
|---|---|---|---|---|---|
| Net income 2024 * | -57M | Net income 2025 * | -69M | EV / Sales 2024 * | 3.37 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.27 x |
| P/E ratio 2024 * |
-1
x | P/E ratio 2025 * |
-1.01
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -10.64% | ||
| 1 week | -8.03% | ||
| Current month | -22.70% | ||
| 1 month | -25.88% | ||
| 3 months | -47.93% | ||
| 6 months | -51.16% | ||
| Current year | -57.00% |
1 week
1.24
1.47
1 month
1.241.71
Current year
1.243.06
1 year
1.249.77
3 years
1.249.77
5 years
1.249.77
10 years
1.249.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 1.26 | -10.64% | 329,739 |
| 24-05-22 | 1.41 | -0.70% | 184,187 |
| 24-05-21 | 1.42 | +0.71% | 100,186 |
| 24-05-20 | 1.41 | 0.00% | 131,765 |
| 24-05-17 | 1.41 | +2.92% | 223,335 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.26
USD
Average target price
7.6
USD
Spread / Average Target
+503.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.00% | 52.34M | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -3.52% | 21.58B | |
| -9.56% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- CARM Stock
